aTyr Pharma, Inc. (ATYR) Fair Value 2026

ATYR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

DANGER (63/100)

Quick Summary — As of 2026-08-28, aTyr Pharma, Inc. (ATYR) trades at $0.54. QOC: 5.0/10. Value Trap Risk: 63/100 (DANGER). 1/13 models active.

Key Facts

Ticker
ATYR
Price
$0.54
Quality Score
5.0/10
Value Trap Risk
63/100
Models Active
1/13
Last Updated
Strength: ML-RIV suggests +35.4% upside with 46% confidence
Risk: Value Trap score of 63 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ATYR?

1 Intrinsic Value Models vs. Current Price ($0.54)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.73 +35.4%

All Models Active

All 1 models are displayed above.

What Is aTyr Pharma, Inc. (ATYR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, aTyr Pharma, Inc. is potentially undervalued at its current price of $0.54. Based on our 13-model framework, aTyr Pharma, Inc.'s intrinsic value is estimated at a median fair value of $0.73 — representing +35.4% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About ATYR?

1 of 13 models are currently active for ATYR. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does ATYR Rank in Biotechnology?

Among 625 Biotechnology stocks, ATYR ranks #304 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

aTyr Pharma, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is ATYR a Value Trap?

CirclFi's Value Trap algorithm assigns ATYR a score of 63/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for aTyr Pharma, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, aTyr Pharma, Inc. earns a quality score of 5.0/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. However, our Value Trap algorithm flags elevated risk — suggesting that apparent cheapness may mask deteriorating fundamentals.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ATYR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ATYR's 1 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy aTyr Pharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

RNACCartesian Therapeutics, Inc.QOC 5.1CADLCandel Therapeutics, Inc.QOC 5.0LIPOLipella Pharmaceuticals Inc.QOC 5.1ZBIOZenas BioPharma, Inc.QOC 5.0EXOZeXoZymes, Inc.QOC 5.1BLTEBelite Bio, IncQOC 5.0GRDXGridAI Technologies Corp.QOC 4.5NCELNewcelX Ltd.QOC 2.2CAICaris Life Sciences, Inc.QOC 6.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: RNAC · CADL · LIPO · ZBIO · EXOZ · BLTE · GRDX · NCEL · CAI · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ATYR?

6 companies across all industries closest to ATYR’s Quality of Company score of 5.0/10.

VRMVroom, Inc.QOC 5.0CHNRChina Natural Resources, Inc.QOC 5.0STAIScanTech AI Systems Inc.QOC 5.0PVLPermianville Royalty TrustQOC 5.0VMNTVemanti Group, Inc.QOC 5.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VRM · CHNR · STAI · PVL · VMNT · NVDA

Where Does ATYR Sit in CirclFi's Biotechnology Rankings?

ATYR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About aTyr Pharma, Inc.’s Valuation?

What is aTyr Pharma, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for aTyr Pharma, Inc. (ATYR). The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ATYR overvalued or undervalued right now?

At $0.54, 1 of 1 active models suggest ATYR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits aTyr Pharma, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.0 mean for ATYR?

aTyr Pharma, Inc.'s QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ATYR?

CirclFi analyzes ATYR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ATYR a value trap in 2026?

aTyr Pharma, Inc.'s Value Trap score is 63/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns aTyr Pharma, Inc. (ATYR) a Quality of Company score of 5.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ATYR/ · Methodology
Primary sources for this ATYR valuation
  • Financial statements: aTyr Pharma, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001339970) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ATYR as of ; valuations recomputed .